コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 As described previously for HDAC3, the neurotoxic effect of H
2 As described previously in Brassica, the S haplotypes of A. l
3 As described previously, a binding site for the integration h
4 As described previously, approximately 50% of the animals dev
5 As described previously, continuum models, such as the Smoluc
6 As described previously, HIV transmission was associated with
7 As described previously, in a degradation system utilizing ra
8 As described previously, screening this library for sequences
9 As described previously, the PDB2PQR web server addresses thi
10 As described previously, this results, in part, from the incr
11 As described previously, two distinct groups of sequences wer
12 As described previously, ZO-1 also forms heterodimers with ZO
15 knock-out female mice exhibited mild obesity and adiposity as described previously, as well as a significant delay in th
16 on-activated chloride currents in parotid acinar cells and, as described previously, displayed postnatal degeneration of
17 for mutations in SRSF2, U2AF1 (synonym U2AF35), ZRSR2, and, as described previously, SF3B1, in the context of other molec
19 We speculate that substrate-assisted catalysis, as described previously for certain RING-associated ubiquitin
20 ngly, the center of these MTOCs did not contain centrioles, as described previously for SAK/PLK4 overexpression [6].
21 translocation pathway through the VirB/D4 secretion channel as described previously for the T-DNA.
24 Two monkeys received a unilateral DRL, as described previously, which removed cutaneous and proprioc
29 ger and older subpopulations differing in clinical features as described previously among patients identified under the V
31 t pathway produces dual incisions 5' to the site of the ICL as described previously but does not release the cross-link.
34 In group 8, rats were pretreated with ODQ (as described previously) before lipopolysaccharide (n = 8).
35 In group 5, rats were pretreated with ODQ (as described previously) before lipoteichoic acid/peptidoglyc
36 s), their temperature dependence, and activation parameters as described previously for wild type ecDHFR.
39 ted corresponding antigens in sieve elements of the phloem, as described previously for all upstream enzymes transforming
40 orresponding to the end of phase 1 of the action potential, as described previously in the Brugada syndrome.
43 and redesigned serotype-specific TS1 (rTS1) and TS4 (rTS4) as described previously in the conventional capsid and premem
44 e generated and their figures of merit are compared to sets as described previously in the literature (e.g. 4, 8, 12, 15
48 In group 6, rats were pretreated with dimethyl sulfoxide (as described previously) before lipoteichoic acid/peptidoglyc
50 cells were identified by staining with HLA tetramers (tet) as described previously and the distribution of CD27 and CD38